文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

脂质悖论存在于 ST 段抬高型心肌梗死患者中,但不存在于非 ST 段抬高型心肌梗死患者中:来自新加坡心肌梗死注册研究的见解。

The Lipid Paradox is present in ST-elevation but not in non-ST-elevation myocardial infarction patients: Insights from the Singapore Myocardial Infarction Registry.

机构信息

Department of Cardiology, National University Heart Centre, Singapore, Singapore.

Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

出版信息

Sci Rep. 2020 Apr 22;10(1):6799. doi: 10.1038/s41598-020-63825-8.


DOI:10.1038/s41598-020-63825-8
PMID:32321961
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7176706/
Abstract

Lowering low-density lipoprotein (LDL-C) and triglyceride (TG) levels form the cornerstone approach of cardiovascular risk reduction, and a higher high-density lipoprotein (HDL-C) is thought to be protective. However, in acute myocardial infarction (AMI) patients, higher admission LDL-C and TG levels have been shown to be associated with better clinical outcomes - termed the 'lipid paradox'. We studied the relationship between lipid profile obtained within 72 hours of presentation, and all-cause mortality (during hospitalization, at 30-days and 12-months), and rehospitalization for heart failure and non-fatal AMI at 12-months in ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) patients treated by percutaneous coronary intervention (PCI). We included 11543 STEMI and 8470 NSTEMI patients who underwent PCI in the Singapore Myocardial Infarction Registry between 2008-2015. NSTEMI patients were older (60.3 years vs 57.7 years, p < 0.001) and more likely to be female (22.4% vs 15.0%, p < 0.001). In NSTEMI, a lower LDL-C was paradoxically associated with worse outcomes for death during hospitalization, within 30-days and within 12-months (all p < 0.001), but adjustment eliminated this paradox. In contrast, the paradox for LDL-C persisted for all primary outcomes after adjustment in STEMI. For NSTEMI patients, a lower HDL-C was associated with a higher risk of death during hospitalization but in STEMI patients a lower HDL-C was paradoxically associated with a lower risk of death during hospitalization. For this endpoint, the interaction term for HDL-C and type of MI was significant even after adjustment. An elevated TG level was not protective after adjustment. These observations may be due to differing characteristics and underlying pathophysiological mechanisms in NSTEMI and STEMI.

摘要

降低低密度脂蛋白(LDL-C)和甘油三酯(TG)水平是降低心血管风险的基础方法,而较高的高密度脂蛋白(HDL-C)被认为是具有保护作用的。然而,在急性心肌梗死(AMI)患者中,较高的入院时 LDL-C 和 TG 水平与更好的临床结局相关,这种现象被称为“血脂悖论”。我们研究了在经皮冠状动脉介入治疗(PCI)的 ST 段抬高型心肌梗死(STEMI)和非 ST 段抬高型心肌梗死(NSTEMI)患者就诊后 72 小时内获得的血脂谱与全因死亡率(住院期间、30 天和 12 个月时)以及心力衰竭和非致命性 AMI 的再住院之间的关系。我们纳入了 2008 年至 2015 年间在新加坡心肌梗死登记处接受 PCI 的 11543 例 STEMI 和 8470 例 NSTEMI 患者。NSTEMI 患者年龄较大(60.3 岁 vs 57.7 岁,p<0.001),且更可能为女性(22.4% vs 15.0%,p<0.001)。在 NSTEMI 中,LDL-C 降低与住院期间、30 天内和 12 个月内的死亡风险增加相关(均 p<0.001),但调整后消除了这种悖论。相反,调整后 STEMI 患者的所有主要结局仍存在 LDL-C 悖论。对于 NSTEMI 患者,较低的 HDL-C 与住院期间死亡风险增加相关,但对于 STEMI 患者,较低的 HDL-C 与住院期间死亡风险降低相关。对于这一终点,即使在调整后,HDL-C 和 MI 类型的交互项仍然具有统计学意义。调整后,TG 水平升高并没有保护作用。这些观察结果可能归因于 NSTEMI 和 STEMI 之间不同的特征和潜在的病理生理机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3cf/7176706/65f3a706d0bd/41598_2020_63825_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3cf/7176706/94909e621570/41598_2020_63825_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3cf/7176706/7326fb3491d0/41598_2020_63825_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3cf/7176706/243501c103c6/41598_2020_63825_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3cf/7176706/6d695cd30911/41598_2020_63825_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3cf/7176706/b74d01d32dad/41598_2020_63825_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3cf/7176706/65f3a706d0bd/41598_2020_63825_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3cf/7176706/94909e621570/41598_2020_63825_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3cf/7176706/7326fb3491d0/41598_2020_63825_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3cf/7176706/243501c103c6/41598_2020_63825_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3cf/7176706/6d695cd30911/41598_2020_63825_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3cf/7176706/b74d01d32dad/41598_2020_63825_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3cf/7176706/65f3a706d0bd/41598_2020_63825_Fig6_HTML.jpg

相似文献

[1]
The Lipid Paradox is present in ST-elevation but not in non-ST-elevation myocardial infarction patients: Insights from the Singapore Myocardial Infarction Registry.

Sci Rep. 2020-4-22

[2]
Impact of renin-angiotensin system inhibitors on long-term clinical outcomes in patients with acute myocardial infarction treated with successful percutaneous coronary intervention with drug-eluting stents: Comparison between STEMI and NSTEMI.

Atherosclerosis. 2018-11-27

[3]
Acute Myocardial Infarction: Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015.

Circulation. 2017-8-27

[4]
Twelve-month clinical outcomes of acute non-ST versus ST-segment elevation myocardial infarction patients with reduced preprocedural thrombolysis in myocardial infarction flow undergoing percutaneous coronary intervention.

Coron Artery Dis. 2018-8

[5]
Characteristics and In-Hospital Outcomes of Patients Who Underwent Coronary Artery Bypass Grafting during Hospitalization for ST-Segment Elevation or Non-ST-Segment Elevation Myocardial Infarction.

Ann Thorac Cardiovasc Surg. 2024-1-25

[6]
The role of remnant cholesterol in patients with ST-segment elevation myocardial infarction.

Eur J Prev Cardiol. 2024-8-9

[7]
Comparison of the cost in percutaneous coronary intervention between ST-segment elevation myocardial infarction vs. non-ST-segment elevation myocardial infarction.

Cardiovasc Interv Ther. 2022-4

[8]
Characteristics, Management, and Outcome of Transient ST-elevation Versus Persistent ST-elevation and Non-ST-elevation Myocardial Infarction.

Am J Cardiol. 2018-6-15

[9]
Prognostic impact of prepercutaneous coronary intervention TIMI flow in patients with ST-segment and non-ST-segment elevation myocardial infarction: Results from the FAST-MI 2010 registry.

Arch Cardiovasc Dis. 2017-9-19

[10]
One-year Outcomes in Patients with ST-segment Elevation Myocardial Infarction Caused by Unprotected Left Main Coronary Artery Occlusion Treated by Primary Percutaneous Coronary Intervention.

Chin Med J (Engl). 2018-6-20

引用本文的文献

[1]
Clinical Outcomes Based on the Attainment of Low-Density Lipoprotein Cholesterol Targets in Patients with Acute Coronary Syndrome in Real-World Practice.

Int J Clin Pract. 2022-12-17

[2]
Low-density lipoprotein cholesterol goal attainment and mortality in ischaemic heart disease: a two-year observational study.

Singapore Med J. 2025-3-1

[3]
Different levels of lipids, Hb1Ac and cytokines among patients with coronary artery disease.

Heliyon. 2024-10-28

[4]
Machine-learning based risk prediction of in-hospital outcomes following STEMI: the STEMI-ML score.

Front Cardiovasc Med. 2024-10-10

[5]
Effectiveness of lipid-lowering therapy on mortality and major adverse cardiovascular event outcomes in patients undergoing percutaneous coronary intervention: a network meta-analysis of randomised controlled trials.

BMJ Open. 2023-11-15

[6]
Association of triglyceride levels with adverse cardiovascular events in patients with ST-segment elevation myocardial infarction.

Heliyon. 2023-6-14

[7]
Association of body mass index, metabolic health status and clinical outcomes in acute myocardial infarction patients: a national registry-based study.

Front Cardiovasc Med. 2023-6-26

[8]
Prediction models for major adverse cardiovascular events following ST-segment elevation myocardial infarction and subgroup-specific performance.

Front Cardiovasc Med. 2023-4-25

[9]
Predictive value of triglycerides to high density lipoprotein ratio in patients with first attack of acute coronary syndrome.

Saudi Med J. 2023-4

[10]
Bioresorbable scaffolds vs. drug-eluting stents for patients with myocardial infarction: A systematic review and meta-analysis of randomized clinical trials.

Front Cardiovasc Med. 2022-10-28

本文引用的文献

[1]
Time-Stratified Case Crossover Study of the Association of Outdoor Ambient Air Pollution With the Risk of Acute Myocardial Infarction in the Context of Seasonal Exposure to the Southeast Asian Haze Problem.

J Am Heart Assoc. 2019-3-19

[2]
Ethnic Differences and Trends in ST-Segment Elevation Myocardial Infarction Incidence and Mortality in a Multi-Ethnic Population.

Ann Acad Med Singap. 2019-3

[3]
Fourth Universal Definition of Myocardial Infarction (2018).

J Am Coll Cardiol. 2018-10-30

[4]
Relationship between low-density lipoprotein cholesterol and severe acute pancreatitis ("the lipid paradox").

Ther Clin Risk Manag. 2018-5-30

[5]
Association of low-density lipoprotein pattern with mortality after myocardial infarction: Insights from the TRIUMPH study.

J Clin Lipidol. 2017-10-3

[6]
Trials and Tribulations of CETP Inhibitors.

Circ Res. 2017-10-10

[7]
Effects of Different Types of Statins on Lipid Profile: A Perspective on Asians.

Int J Endocrinol Metab. 2017-4-22

[8]
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

N Engl J Med. 2017-8-27

[9]
Ministry of Health Clinical Practice Guidelines: Lipids.

Singapore Med J. 2017-3

[10]
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

Eur Heart J. 2016-10-14

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索